^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | nafamostat (TMPRSS2 inhibitor, Serine protease inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
Published date:
12/07/2021
Excerpt:
The similar result was also observed in another ERPBC cell line with endocrine resistance (supplementary Fig. 1A and B). The proliferation of MCF7-TamR and MCF7-FulR cells was also significantly decreased by a serial dose (30 to 90 μM) of NM (Fig. 1C and D). NM also caused significant apoptosis of MCF7-TamR and MCF7-FulR cells in a dose-dependent manner (Fig. 2A and B).
DOI:
10.1016/j.tranon.2021.101302
